Advertisement
Screener

IRONWOOD PHARMACEUTICALS, INC. (IRWD) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

2.1 / 5 stars · 41/100 Roast Me

IRONWOOD PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$265.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-18.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2022-02-18

  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2020-12-31 was -$28.00K.
  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2020-09-30 was $0.00.
  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2020-06-30 was -$376.00K.
  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2020-03-31 was -$1.44M, a 215.41% decline year-over-year.
  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2021 was -$265.00K.
  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2020 was -$1.84M.
  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2019 was -$6.92M, a 107.13% decline from fiscal 2018.
  • IRONWOOD PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2018 was $97.14M, a 36.46% decline from fiscal 2017.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2021-12-31-$265.00K
10-K · filed 2022-02-18
2020-12-31-$28.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18
-$28.00K
derived: sum of 2 quarters · filed 2022-02-18
-$404.00K
derived: sum of 3 quarters · filed 2022-02-18
-$1.84M
10-K · filed 2022-02-18
2020-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$376.00K
derived: sum of 2 quarters · filed 2020-11-05
-$1.81M
10-Q · filed 2020-11-05
-$4.47M
derived: sum of 4 quarters · filed 2022-02-18
2020-06-30-$376.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$1.81M
10-Q · filed 2020-08-06
-$4.47M
derived: sum of 3 quarters · filed 2022-02-18
-$7.55M
derived: sum of 4 quarters · filed 2022-02-18
2020-03-31-$1.44M
10-Q · filed 2020-05-06
-$4.10M
derived: sum of 2 quarters · filed 2022-02-18
-$7.18M
derived: sum of 3 quarters · filed 2022-02-18
-$9.61M
derived: sum of 4 quarters · filed 2022-02-18
2019-12-31-$2.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18
-$5.74M
derived: sum of 2 quarters · filed 2022-02-18
-$8.17M
derived: sum of 3 quarters · filed 2022-02-18
-$6.92M
10-K · filed 2022-02-18
2019-09-30-$3.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$5.51M
derived: sum of 2 quarters · filed 2020-11-05
-$4.26M
10-Q · filed 2020-11-05
$16.27M
derived: sum of 4 quarters · filed 2021-02-17
2019-06-30-$2.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$1.18M
10-Q · filed 2020-08-06
$19.35M
derived: sum of 3 quarters · filed 2021-02-17
$37.11M
derived: sum of 4 quarters · filed 2021-02-17
2019-03-31$1.25M
10-Q · filed 2020-05-06
$21.78M
derived: sum of 2 quarters · filed 2021-02-17
$39.53M
derived: sum of 3 quarters · filed 2021-02-17
2018-12-31$20.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17
$38.29M
derived: sum of 2 quarters · filed 2021-02-17
$97.14M
10-K · filed 2021-02-17
2018-09-30$17.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
$76.60M
10-Q · filed 2019-10-31
2018-06-30$58.85M
10-Q · filed 2019-07-30
2017-12-31$152.87M
10-K · filed 2020-02-13
2017-03-31$88.06M
10-Q · filed 2017-05-08
2016-09-30-$90.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
-$85.60M
derived: sum of 2 quarters · filed 2016-11-07
-$62.25M
10-Q · filed 2016-11-07
-$27.34M
derived: sum of 4 quarters · filed 2017-05-08
2016-06-30$4.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
$28.11M
10-Q · filed 2016-08-08
$63.02M
derived: sum of 3 quarters · filed 2017-05-08
$84.86M
derived: sum of 4 quarters · filed 2017-05-08
2016-03-31$23.35M
10-Q · filed 2017-05-08
$58.26M
derived: sum of 2 quarters · filed 2017-05-08
$80.09M
derived: sum of 3 quarters · filed 2017-05-08
-$5.57M
derived: sum of 4 quarters · filed 2017-05-08
2015-12-31$34.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19
$56.74M
derived: sum of 2 quarters · filed 2016-11-07
-$28.91M
derived: sum of 3 quarters · filed 2016-11-07
-$9.15M
10-K · filed 2016-02-19
2015-09-30$21.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
-$63.83M
derived: sum of 2 quarters · filed 2016-11-07
-$44.07M
10-Q · filed 2016-11-07
-$5.75M
derived: sum of 4 quarters · filed 2016-11-07
2015-06-30-$85.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
-$65.90M
10-Q · filed 2016-08-08
-$27.59M
derived: sum of 3 quarters · filed 2016-08-08
-$35.47M
derived: sum of 4 quarters · filed 2016-08-08
2015-03-31$19.76M
10-Q · filed 2016-05-10
$58.07M
derived: sum of 2 quarters · filed 2016-05-10
$50.19M
derived: sum of 3 quarters · filed 2016-05-10
2014-12-31$38.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19
$30.43M
derived: sum of 2 quarters · filed 2016-02-19
-$56.57M
10-K · filed 2016-02-19
2014-09-30-$7.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05
-$94.88M
10-Q · filed 2015-11-05
2014-06-30-$87.00M
10-Q · filed 2015-08-07
2013-12-31-$101.43M
10-K · filed 2016-02-19
2012-12-31$32.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
$31.55M
derived: sum of 2 quarters · filed 2013-02-21
$28.79M
derived: sum of 3 quarters · filed 2013-02-21
$30.08M
10-K · filed 2013-02-21
2012-09-30-$680.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
-$3.44M
derived: sum of 2 quarters · filed 2012-11-06
-$2.15M
10-Q · filed 2012-11-06
$23.40M
derived: sum of 4 quarters · filed 2013-02-21
2012-06-30-$2.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07
-$1.47M
10-Q · filed 2012-08-07
$24.08M
derived: sum of 3 quarters · filed 2013-02-21
$69.56M
derived: sum of 4 quarters · filed 2013-02-21
2012-03-31$1.29M
10-Q · filed 2012-05-10
$26.83M
derived: sum of 2 quarters · filed 2013-02-21
$72.32M
derived: sum of 3 quarters · filed 2013-02-21
$91.15M
derived: sum of 4 quarters · filed 2013-02-21
2011-12-31$25.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
$71.03M
derived: sum of 2 quarters · filed 2013-02-21
$89.86M
derived: sum of 3 quarters · filed 2013-02-21
$115.06M
10-K · filed 2013-02-21
2011-09-30$45.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
$64.31M
derived: sum of 2 quarters · filed 2012-11-06
$89.52M
10-Q · filed 2012-11-06
$75.05M
derived: sum of 4 quarters · filed 2013-02-21
2011-06-30$18.83M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07
$44.04M
10-Q · filed 2012-08-07
$29.57M
derived: sum of 3 quarters · filed 2013-02-21
$76.26M
derived: sum of 4 quarters · filed 2013-02-21
2011-03-31$25.21M
10-Q · filed 2012-05-10
$10.74M
derived: sum of 2 quarters · filed 2013-02-21
$57.43M
derived: sum of 3 quarters · filed 2013-02-21
2010-12-31-$14.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
$32.23M
derived: sum of 2 quarters · filed 2013-02-21
-$213.04M
10-K · filed 2013-02-21
2010-09-30$46.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09
-$198.57M
10-Q · filed 2011-11-09
2010-06-30-$245.27M
10-Q · filed 2011-08-12
2009-12-31$18.28M
10-K · filed 2012-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
Verastem, Inc. (VSTM)United States$0.706B-1.71
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Faeth Therapeutics, Inc. (FTH)United States$0.750B
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Neurogene Inc. (NGNE)$0.625B-4.46
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78